Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ADME of JNJ-39823277 in Healthy Males
NCT02049697Phase 1Completed
- Sponsor
- Johnson & Johnson
- Start
- Apr 2009
- Primary completion
- May 2009
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of tianeptine in solid tumor, sponsored by Johnson & Johnson. Primary endpoint: Maximum observed plasma concentration at 168 hours. Started Apr 2009; status: completed.
02
Drugs
tianeptine
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT02049697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02049697.